View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Mannkind Corp: 1 director

A director at Mannkind Corp bought 100,000 shares at 2.590USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

Wedbush Research
  • Wedbush Research
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Robert Driscoll
  • Thomas Yip
  • Yun Zhong

The Week Ahead in Life Sciences

Arcus Biosciences (RCUS) Feb. 28, 2026: Additional ARC-20 data including activity and biomarker analysis of cas in ccRCCAscendis Pharma (ASND) Feb. 28, 2026: PDUFA date for TransCon CNP for pediatric achondroplasiaBioMarin Pharmaceutical (BMRN) Feb. 28, 2026: PDUFA date for Palynziq for adolescent

David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Robert Driscoll
  • Thomas Yip
  • Yun Zhong
Yun Zhong
  • Yun Zhong

Good Progress On Afrezza Towards 5/29/2026 PDUFA

Figure 1 - Original Dose Conversion TableSource: FDAFigure 2 - Updated Dose Conversion TableSource: Company dataFigure 3 - Updated Starting Dose Reduces Postprandial Peak GlucoseSource: Company data

Yun Zhong
  • Yun Zhong

MNKD-101 Discontinued But -102 Moves Forward; PT To $10

MNKD-201 in IPF will Have a Ph1b Study in the U.S. Management also disclosed the plan to initiate a Ph1b trial in approximately 30 IPF patients, who will receive seven days of treatment with MNKD-201 at the Ph2 doses. Data to be available in 2Q26 will confirm DPI's tolerability in IPF patients and

Yun Zhong
  • Yun Zhong
Yun Zhong
  • Yun Zhong

Afrezza sBLA For Adolescent Patients Accepted; PDUFA 5/29/2026

Future Clinical Studies Could Further Expand Afrezza's PotentialSource: Company presentation

 PRESS RELEASE

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Reve...

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc. The acquisition of scPharmaceuticals is expected to diversify and accelerate MannKind’s double-digit revenue growth, driven by FUROSCIX® (furosemide injection), an innovative therapy for edema due to chronic heart failure and chronic kidney disease. The transaction will strengthen MannKind’s co...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch